Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 27861698)

Published in J Am Geriatr Soc on November 12, 2016

Authors

Jeffrey M Ashburner¹^,2, Alan S Go³^,4^,5, Yuchiao Chang¹, Margaret C Fang⁶, Lisa Fredman², Katie M Applebaum⁷, Daniel E Singer¹

Author Affiliations

1: Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts.
2: Epidemiology Department, School of Public Health, Boston University, Boston, Massachusetts.
3: Division of Research, Kaiser Permanente Northern California, Oakland, California.
4: Department of Epidemiology, Biostatistics and Medicine, University of California, San Francisco, San Francisco, California.
5: Department of Health Research and Policy, School of Medicine, Stanford University, Stanford, California.
6: Department of Medicine, University of California, San Francisco, San Francisco, California.
7: Department of Environmental and Occupational Health, Milken Institute, School of Public Health, George Washington University, Washington, District of Columbia.

Articles cited by this ↗

A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med (2004) 49.19

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA (2001) 24.12

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22.23

Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest (2009) 14.06

ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 11.49

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med (1994) 10.26

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet (2007) 10.10

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96

Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med (1987) 8.09

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace (2012) 7.33

Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med (2000) 5.41

Competing risk regression models for epidemiologic data. Am J Epidemiol (2009) 4.75

The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med (2009) 4.71

Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med (1999) 4.54

Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med (2010) 4.15

Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA (2003) 4.13

The use and interpretation of competing risks regression models. Clin Cancer Res (2012) 3.01

Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc (1997) 2.09

A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med (1984) 2.06

Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc (2010) 2.01

The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med (1997) 1.93

Risks of Death and Stroke in Patients Undergoing Hemodialysis With New-Onset Atrial Fibrillation: A Competing-Risk Analysis of a Nationwide Cohort. Circulation (2015) 1.50

Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. Br J Gen Pract (2012) 1.46

Preventing stroke in patients with atrial fibrillation. JAMA (1999) 1.22

A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc (2013) 1.14

Methods of competing risks analysis of end-stage renal disease and mortality among people with diabetes. BMC Med Res Methodol (2010) 1.12

[An introduction to competing risks analysis]. Rev Esp Cardiol (2011) 1.01

Articles by these authors ⇆

Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study. J Am Coll Cardiol (2016) 1.39

Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts). Am J Cardiol (2014) 0.77